TY - JOUR
T1 - Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone
T2 - A case report and systematic review
AU - Wojtowicz, Jeremy M.
AU - Yarema, Mark C.
AU - Wax, Paul M.
PY - 2008/1
Y1 - 2008/1
N2 - 1,4-Butanediol (1,4-BD) is an industrial solvent that is metabolized to gamma-hydroxybutyrate (GHB), a gamma-aminobutyric acid agonist and central nervous system depressant. GHB and its analogues are popular drugs of abuse. Withdrawal from these agents is characterized by autonomic instability and altered mental status. We report a case of withdrawal from 1,4-BD lasting 6 days and complicated by new onset of seizures and rhabdomyolysis. In addition, we conducted a systematic review of the English literature pertaining to withdrawal from GHB, 1,4-BD and gamma-butyrolactone (GBL). Data collected from source articles included last use prior to symptom onset, clinical features on presentation. duration of symptoms and outcome. Twenty-seven studies with 57 episodes of withdrawal were included. Thirty-six cases (63%) involved GHB, 3 cases (5%) involved 1,4-BD and 18 (32%) involved GBL. The most common patient symptoms were tremor (67%), hallucinations (63%), tachycardia (63%) and insomnia (58%). Seizures and rhabdomyolysis each occurred in 7% of cases, but only 1 death occurred. Emergency physicians must consider withdrawal from these agents when patients present with clinical features suggestive of a sedative-hypnotic withdrawal syndrome.
AB - 1,4-Butanediol (1,4-BD) is an industrial solvent that is metabolized to gamma-hydroxybutyrate (GHB), a gamma-aminobutyric acid agonist and central nervous system depressant. GHB and its analogues are popular drugs of abuse. Withdrawal from these agents is characterized by autonomic instability and altered mental status. We report a case of withdrawal from 1,4-BD lasting 6 days and complicated by new onset of seizures and rhabdomyolysis. In addition, we conducted a systematic review of the English literature pertaining to withdrawal from GHB, 1,4-BD and gamma-butyrolactone (GBL). Data collected from source articles included last use prior to symptom onset, clinical features on presentation. duration of symptoms and outcome. Twenty-seven studies with 57 episodes of withdrawal were included. Thirty-six cases (63%) involved GHB, 3 cases (5%) involved 1,4-BD and 18 (32%) involved GBL. The most common patient symptoms were tremor (67%), hallucinations (63%), tachycardia (63%) and insomnia (58%). Seizures and rhabdomyolysis each occurred in 7% of cases, but only 1 death occurred. Emergency physicians must consider withdrawal from these agents when patients present with clinical features suggestive of a sedative-hypnotic withdrawal syndrome.
KW - 1,4-butanediol
KW - Gamma-butyrolactone
KW - Gamma-hydroxybutyrate
KW - Substance withdrawal syndrome
UR - http://www.scopus.com/inward/record.url?scp=47249117171&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47249117171&partnerID=8YFLogxK
U2 - 10.1017/S1481803500010034
DO - 10.1017/S1481803500010034
M3 - Article
C2 - 18226321
AN - SCOPUS:47249117171
SN - 1481-8035
VL - 10
SP - 69
EP - 74
JO - Canadian Journal of Emergency Medicine
JF - Canadian Journal of Emergency Medicine
IS - 1
ER -